EQRX News and Press, EQRx Inc. From 12/02/22

Submission is EQRx’s first to European Medicines Agency Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -...

Summary Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Wuhan Neurophth announced a $140 million agreement to use Cyagen’s AI platform to discover novel AAV vectors. Harbour BioMed will use its antibody disc...

EQRx, Inc. (EQRX) Q3 2022 Earnings Conference Call November 10, 2022 08:00 ET Company Participants Neil Swami - Head, Investor Relations Melanie Nallicheri - President and Chief Executive Officer Jami Rubin - Chief Financial Officer Eric Hedrick - Chief Physi...

The following slide deck was published by EQRx, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: EQRx, Inc. 2022 Q3 - Results - Earnings Call Presentation

EQRx, Inc. ( NASDAQ: EQRX ) sold off for the second straight session on Friday as Goldman Sachs and Jefferies downgraded the cancer-focused biotech in reaction to the pipeline updates the company shared with its Q3 2022 financials yesterday. Following regulatory feedback...

Shares of EQRx (NASDAQ: EQRX) dropped 28.62% on Thursday. The stock stood at $5.45 at Wednesday's close and opened on Thursday much lower at $4.70. Shares fell to as low as $3.44 before rallying a bit at the close to $3.89. The stock has a 52-week low of $2.63 and a 52-week high of ...

Summary The company has abandoned their compete-on-price strategy, at least for their first two drugs, and I will be surprised if we ever hear about that part again, either. They were bringing along an EGFR inhibitor that was extremely similar to AstraZeneca’s Tagrisso, and...

EQRx, Inc. ( NASDAQ: EQRX ), a biotech focused on oncology, dropped ~15% in the morning hours Thursday after its Q3 2022 financials as investors reacted to the pipeline updates the company announced in response to FDA feedback. Notable updates include a decision to drop ...

EQRx press release ( NASDAQ: EQRX ): Q3 GAAP EPS of -$0.18 beats by $0.03 . “With clear regulatory guidance on a pathway for aumolertinib in the U.S., we are adapting and believe that utilizing a market-based pricing approach for our lead cancer programs, a...

Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.’s MHRA Sugemalimab: Based on recent FDA feedback, EQRx has concluded that there is no commercially viable path for sugemalimab p...